Tevogen Bio Holdings Inc. TVGN 深 沪
等待开盘 03-26 09:30:00 美东时间
5.10
-0.120
-2.30%
华盛通- 最 高5.64
- 今 开5.23
- 成交量 1.70万股
- 最 低 5.00
- 昨 收 5.22
- 总市值 2055.50万
- 52周最高 75.50
- 市盈率 静 --
- 换手率 0.42%
- 52周最低 4.892
- 委 比 -53.38%
- 总股本 403.04万
- 历史最高 1054.50
- 量 比 0.61
- 振 幅 12.26%
- 历史最低 5.00
- 每 手 1
- 风险率 18.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tevogen Bio Regains Nasdaq Compliance
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) received written notice (the "Notification Letter") from The Nasdaq Stock Market LLC notifying the Company that it had regained compliance with the minimum
10分钟前
Tevogen Reports Advanced Performance For Its AI Platform; Recent Testing Of PredicTcell Model Shows Recall Enhancement From 87% To 92%, Improved Precision From 40% To 48%
Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today announced performance advancements for its artificial intelligence platform, operated through Tevogen.AI.Tevogen.AI was built to solve a critical
03-14 00:32
Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure
Tevogen.AI has enhanced its PredicTcell™ model, improving prediction accuracy to 92% and precision to 48%, with a 20x increase in robustness. The company expanded its peptide database to over 655 million sequences, leveraging AI to accelerate drug discovery, reduce costs, and improve clinical success rates. Tevogen plans to partner with pharma companies to advance peptide candidates and further innovate in immunotherapy.
03-13 16:30
Tevogen Names Leadership Team to Execute Diversified Growth Strategy
Tevogen has appointed interim leaders for its core business verticals to advance its diversified growth strategy, with potential annual revenues exceeding $50 million. Leaders in Digital Health, Generics, Contract Research, Biotech, and Artificial Intelligence have been designated. The company expects to finalize transactions by Q2 2026. Tevogen focuses on affordable, efficient healthcare solutions through AI, precision T cell therapy, and collab...
03-09 11:45
Marvell Technology, Day One Biopharmaceuticals, Samsara And Other Big Stocks Moving Higher On Friday
Dow Jones falls 500 points on Friday, Marvell Technology shares jump 18.4%, other stocks recording gains include DAWN, BATL, RCAT, and SWBI.
03-06 23:37
Letter to Shareholders from CEO Dr. Ryan Saadi
This press release updates shareholders on Tevogen's strategic initiatives, including potential acquisitions to complement its immunotherapy and AI platforms. If successful, these transactions aim to generate positive cash flow and returns, potentially exceeding $50 million annually. Tevogen emphasizes disciplined growth, affordability, and long-term value creation. The company is exploring initiatives in generics, biosimilars, medical devices, a...
03-06 20:40
Tevogen Bio Holdings Signs Letter Of Intent To Evaluate Potential Acquisition Of Apozeal Pharmaceutical
If consummated, the potential acquisition of Apozeal could provide Tevogen with an established generics platform, including:11 FDA-approved Abbreviated New Drug Application (ANDA) products for the U.S. marketMultiple
03-06 03:51
Tevogen Bio Announces 1-for-50 Reverse Stock Split
Tevogen Bio Holdings ( ($TVGN) ) has shared an announcement. On March 3, 2026, ...
03-04 22:31
Tevogen Bio Holdings approves 50-for-1 reverse stock split
Tevogen Bio Holdings approves 50-for-1 reverse stock split Tevogen Bio Holdings Inc. said its board approved a 1-for-50 reverse stock split after shareholders authorized it on Feb. 19, 2026. The company expects the split to take effect at 12:01 a.m. on March 6, 2026, with shares trading on a split-a
03-04 21:01
Tevogen Announces Reverse Stock Split
Tevogen announced its Board of Directors has approved a 50-for-1 reverse stock split to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The split, previously approved by stockholders, is expected to take effect on March 6, 2026. Each 50 shares will convert into 1 share; fractional shares will be compensated in cash. The split won't affect ownership percentages or company operations, with Tevogen directors and executives ownin...
03-04 13:00
